Tech Company Financing Transactions
Crystalys Therapeutics Funding Round
Frazier Life Sciences, Abrdn and Alexandria Venture Investments invested in a $130 million Series B funding round for Crystalys Therapeutics. The financing round was announced on 7/22/2026.
Transaction Overview
Company Name
Announced On
7/22/2026
Transaction Type
Venture Equity
Amount
$130,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to support the late-stage global clinical development and commercialization preparation of dotinurad, a new, once daily, oral URAT1 inhibitor.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
12544 High Bluff Dr. 310
San Diego, CA 92130
USA
San Diego, CA 92130
USA
Phone
Undisclosed
Website
Email Address
Overview
Crystalys Therapeutics' mission is to address the significant unmet medical needs of people living with gout. Guided by a focused commitment to scientific innovation and a passion for improving patient care, we develop targeted therapies to better control uric acid, reduce flares, resolve tophi and help prevent long-term joint damage. With agility, diligence, and compassion, we strive to deliver meaningful, lasting improvements in patient outcomes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
James Mackay
Chief Financial Officer
Justin Thacker
Chief Medical Officer
Nihar Bhakta
Chief Operating Officer
Ashwin Ram
VP - Bus. Development
DeAnne Reid
Browse more venture capital transactions:
Prev: 7/22/2026: Inner Logic venture capital transaction
Next: 7/22/2026: Uniti AI venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC transactions reported here come from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs